245 related articles for article (PubMed ID: 22971164)
1. Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange.
Costa LJ; Abbas J; Ortiz-Cruz KL; Kang Y; Stuart RK
Eur J Haematol; 2012 Nov; 89(5):432-4. PubMed ID: 22971164
[No Abstract] [Full Text] [Related]
2. Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure.
Malani AK; Gupta V; Rangineni R
Acta Haematol; 2006; 116(4):255-8. PubMed ID: 17119326
[TBL] [Abstract][Full Text] [Related]
3. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
[TBL] [Abstract][Full Text] [Related]
4. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment.
Li J; Zhou DB; Jiao L; Duan MH; Zhang W; Zhao YQ; Shen T
Clin Lymphoma Myeloma; 2009 Oct; 9(5):394-8. PubMed ID: 19858061
[TBL] [Abstract][Full Text] [Related]
6. [Significance of bortezomib and dexamethasone therapy for multiple myeloma showing a serum creatinine level above 2 mg/dl].
Sekiguchi N; Takezako N; Haga M; Nagata A; Noto S; Miwa A
Rinsho Ketsueki; 2011 Feb; 52(2):87-9. PubMed ID: 21403430
[TBL] [Abstract][Full Text] [Related]
7. [Combination of bortezomib and dexamethasone for newly diagnosed multiple myeloma].
Li J; Zeng LJ; Zhao Y; Su C; Huang BH
Zhonghua Xue Ye Xue Za Zhi; 2009 Aug; 30(8):543-7. PubMed ID: 19954643
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathy.
Howman R; Thakerer A; Pitman M; Ding N; Thompson PA; Khot A; Harrison SJ
Leuk Lymphoma; 2010 Dec; 51(12):2299-302. PubMed ID: 20929329
[No Abstract] [Full Text] [Related]
9. Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
Buda G; Orciuolo E; Galimberti S; Pelosini M; Petrini M
Ann Hematol; 2011 Sep; 90(9):1115-6. PubMed ID: 21181162
[No Abstract] [Full Text] [Related]
10. Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma.
Fu W; Delasalle K; Wang J; Song S; Hou J; Alexanian R; Wang M
Am J Clin Oncol; 2012 Dec; 35(6):562-5. PubMed ID: 21694573
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment.
Song MK; Chung JS; Shin HJ; Moon JH; Lee JJ; Yoon SS; Kim JS; Lee JO; Do YR; Lee HS; Park EK;
Ann Hematol; 2012 Jun; 91(6):889-96. PubMed ID: 22237937
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
Hasegawa M; Kondo F; Yamamoto K; Murakami K; Tomita M; Nabeshima K; Nakai S; Kato M; Ohashi A; Arai J; Hiki Y; Ishii J; Emi N; Sugiyama S; Yuzawa Y
Ther Apher Dial; 2010 Oct; 14(5):451-6. PubMed ID: 21175542
[TBL] [Abstract][Full Text] [Related]
14. [Effect of Velcade combined with Dexamethasone on multiple myeloma].
He Q; Zhao X; He Y; Tan D
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Aug; 35(8):864-7. PubMed ID: 20818081
[TBL] [Abstract][Full Text] [Related]
15. Management of myeloma-associated renal dysfunction in the era of novel therapies.
Gaballa MR; Laubach JP; Schlossman RL; Redman K; Noonan K; Mitsiades CS; Ghobrial IM; Munshi N; Anderson KC; Richardson PG
Expert Rev Hematol; 2012 Feb; 5(1):51-66; quiz 67-8. PubMed ID: 22272706
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of bortezomib combined dexamethasone in 24 patients with multiple myeloma].
Li J; Zhao Y; Luo SK; Huang BH; Ding Y; Tong XZ; Wang HH; Zheng D; Su C; Peng AH
Ai Zheng; 2008 Apr; 27(4):429-34. PubMed ID: 18423132
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib in multiple myeloma: treatment and retreatment. A single center experience.
Warzocha K; Kraj M; Pogłód R; Kwaśniak B
Acta Pol Pharm; 2008; 65(6):753-6. PubMed ID: 19172860
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
San-Miguel JF; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh JD; Neuwirth R; Boral AL; Esseltine DL; Anderson KC
Leukemia; 2008 Apr; 22(4):842-9. PubMed ID: 18200040
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.
Nozza A; Siracusano L; Armando S
Clin Ther; 2006 Jun; 28(6):953-9. PubMed ID: 16860177
[TBL] [Abstract][Full Text] [Related]
20. A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.
Ahn JS; Yang DH; Jung SH; Park HC; Moon JH; Sohn SK; Bae SY; Kim YK; Kim HJ; Lee JJ;
Ann Hematol; 2012 Jul; 91(7):1023-30. PubMed ID: 22314843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
